CUEDC2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using GH1 mouse mAb (green) and negative control (red).    

  
  

The CUEDC2 (CUE domain-containing protein 2) antibody is a crucial tool for studying the role of CUEDC2 in cellular regulation and disease pathogenesis. CUEDC2 is a ubiquitin-binding protein involved in diverse processes, including inflammation, cell cycle progression, and apoptosis. It interacts with key signaling pathways, such as the NF-κB and estrogen receptor (ER) pathways, by modulating protein ubiquitination and degradation. For example, CUEDC2 promotes IκBα degradation to activate NF-κB and enhances ERα ubiquitination, linking it to hormone-responsive cancers. Dysregulation of CUEDC2 has been implicated in tumorigenesis, with overexpression observed in breast, ovarian, and cervical cancers, where it correlates with poor prognosis and therapy resistance.

CUEDC2 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect CUEDC2 expression levels and localization in tissues or cell lines. These antibodies aid in exploring CUEDC2’s functional mechanisms, such as its role in chemoresistance or immune evasion. Commercial CUEDC2 antibodies are typically validated for specificity using knockout controls or siRNA-mediated silencing. Research utilizing these reagents has highlighted CUEDC2 as a potential therapeutic target, particularly in cancers with aberrant ubiquitination pathways. However, variability in antibody performance across experimental conditions necessitates careful optimization to ensure reproducibility in studies.